S&P 500   5,139.55 (+0.32%)
DOW   38,131.90 (+0.39%)
QQQ   438.72 (+0.10%)
AAPL   175.49 (-0.60%)
MSFT   422.16 (+0.06%)
META   508.96 (-0.57%)
GOOGL   158.42 (+0.44%)
AMZN   186.72 (+0.32%)
TSLA   166.77 (-2.50%)
NVDA   889.64 (+0.88%)
AMD   162.93 (-0.21%)
NIO   3.95 (-3.89%)
BABA   71.33 (+0.06%)
T   16.36 (+0.31%)
F   12.47 (-1.11%)
MU   123.79 (+1.04%)
GE   155.08 (+0.29%)
CGC   7.30 (-6.41%)
DIS   114.20 (+0.17%)
AMC   2.61 (-1.51%)
PFE   26.07 (+0.81%)
PYPL   64.79 (+0.31%)
XOM   120.64 (+0.22%)
S&P 500   5,139.55 (+0.32%)
DOW   38,131.90 (+0.39%)
QQQ   438.72 (+0.10%)
AAPL   175.49 (-0.60%)
MSFT   422.16 (+0.06%)
META   508.96 (-0.57%)
GOOGL   158.42 (+0.44%)
AMZN   186.72 (+0.32%)
TSLA   166.77 (-2.50%)
NVDA   889.64 (+0.88%)
AMD   162.93 (-0.21%)
NIO   3.95 (-3.89%)
BABA   71.33 (+0.06%)
T   16.36 (+0.31%)
F   12.47 (-1.11%)
MU   123.79 (+1.04%)
GE   155.08 (+0.29%)
CGC   7.30 (-6.41%)
DIS   114.20 (+0.17%)
AMC   2.61 (-1.51%)
PFE   26.07 (+0.81%)
PYPL   64.79 (+0.31%)
XOM   120.64 (+0.22%)
S&P 500   5,139.55 (+0.32%)
DOW   38,131.90 (+0.39%)
QQQ   438.72 (+0.10%)
AAPL   175.49 (-0.60%)
MSFT   422.16 (+0.06%)
META   508.96 (-0.57%)
GOOGL   158.42 (+0.44%)
AMZN   186.72 (+0.32%)
TSLA   166.77 (-2.50%)
NVDA   889.64 (+0.88%)
AMD   162.93 (-0.21%)
NIO   3.95 (-3.89%)
BABA   71.33 (+0.06%)
T   16.36 (+0.31%)
F   12.47 (-1.11%)
MU   123.79 (+1.04%)
GE   155.08 (+0.29%)
CGC   7.30 (-6.41%)
DIS   114.20 (+0.17%)
AMC   2.61 (-1.51%)
PFE   26.07 (+0.81%)
PYPL   64.79 (+0.31%)
XOM   120.64 (+0.22%)
S&P 500   5,139.55 (+0.32%)
DOW   38,131.90 (+0.39%)
QQQ   438.72 (+0.10%)
AAPL   175.49 (-0.60%)
MSFT   422.16 (+0.06%)
META   508.96 (-0.57%)
GOOGL   158.42 (+0.44%)
AMZN   186.72 (+0.32%)
TSLA   166.77 (-2.50%)
NVDA   889.64 (+0.88%)
AMD   162.93 (-0.21%)
NIO   3.95 (-3.89%)
BABA   71.33 (+0.06%)
T   16.36 (+0.31%)
F   12.47 (-1.11%)
MU   123.79 (+1.04%)
GE   155.08 (+0.29%)
CGC   7.30 (-6.41%)
DIS   114.20 (+0.17%)
AMC   2.61 (-1.51%)
PFE   26.07 (+0.81%)
PYPL   64.79 (+0.31%)
XOM   120.64 (+0.22%)
OTCMKTS:RSPI

RespireRx Pharmaceuticals (RSPI) Stock Price, News & Analysis

$0.0009
+0.00 (+12.50%)
(As of 04/12/2024 08:53 PM ET)
Today's Range
$0.0008
$0.0010
50-Day Range
N/A
52-Week Range
$0.0006
$0.0191
Volume
8.49 million shs
Average Volume
13.32 million shs
Market Capitalization
$697,212.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RSPI stock logo

About RespireRx Pharmaceuticals Stock (OTCMKTS:RSPI)

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

RSPI Stock Price History

RSPI Stock News Headlines

2024 Oil Boom
Wall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.
2024 Oil Boom
Wall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.
Alnylam Pharmaceuticals (NASDAQ: ALNY)
RespireRx Pharmaceuticals Inc. (RSPI)
RSPI RespireRx Pharmaceuticals Inc.
See More Headlines
Receive RSPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RespireRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/19/2020
Today
4/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:RSPI
Employees
2
Year Founded
N/A

Profitability

Net Income
$-2,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.09) per share

Miscellaneous

Free Float
387,109,000
Market Cap
$697,212.00
Optionable
Not Optionable
Beta
0.49
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Arnold S. Lippa Ph.D. (Age 77)
    Executive Chairman, Interim President, Interim CEO & Chief Scientific Officer
    Comp: $339.6k
  • Dr. Jeff Eliot Margolis (Age 68)
    Senior VP, CFO, Treasurer, Secretary & Director
    Comp: $321.6k
  • Mr. Richard D. Purcell (Age 63)
    Senior Vice President of Research & Development
    Comp: $199.86k
  • Mr. David Dickason (Age 60)
    Senior Vice President of Pre-Clinical Product Development
  • Mr. Marc M. Radin
    Controller

RSPI Stock Analysis - Frequently Asked Questions

How have RSPI shares performed in 2024?

RespireRx Pharmaceuticals' stock was trading at $0.0009 at the beginning of 2024. Since then, RSPI shares have increased by 0.0% and is now trading at $0.0009.
View the best growth stocks for 2024 here
.

How were RespireRx Pharmaceuticals' earnings last quarter?

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) issued its quarterly earnings data on Wednesday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter.

What other stocks do shareholders of RespireRx Pharmaceuticals own?
How do I buy shares of RespireRx Pharmaceuticals?

Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:RSPI) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners